The US Food and Drug Administration (FDA) announced Abbott is recalling the HeartMate 3™ Left Ventricular Assist System. The FDA said it has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.
The HeartMate 3™ Left Ventricular Assist System helps deliver blood from the heart to the rest of the body. It is used for short-term support of patients who are at risk of death from end-stage left ventricular heart failure, such as patients awaiting a heart transplant. The system includes a blood pump that is implanted in the space around the heart (pericardium) along with an outflow graft that connects the pump to the aorta.
Abbott is recalling the HeartMate 3™ Left Ventricular Assist System due to a malfunction in the device’s outflow graft assembly that may cause the outflow graft to twist and close up (occlusion) over time.
Occlusion of the outflow graft can reduce or stop pump flow and set off a persistent low flow alarm in the system. A reduction in the pump can lead to serious adverse events such as blood clots and death.
FDA has stated that patients experiencing a persistent low flow alarm should contact the physician managing their HeartMate 3™ Left Ventricular Assist System immediately. Abbott is recommending not to remove the device because of this issue.
Abbott has recalled its product HeartMate 3 system, model/item numbers: catalog #106524US (US commercial), 106524 (US Investigational Device Exemption number), and 10652INT (international). The recall affects all lots and all manufacturing dates with distribution between September 2, 2014, and present. Recalled systems in the United States total 4878 devices nationwide.
Abbott sent an Urgent Medical Device Recall notification to physicians on May 21, alerting them again to the device malfunction and providing them with instructions for managing patients getting the device or patients who already have the device implanted.
Following are the instructions:
- Patients should be followed per recommendations from the American Society of Echocardiography (J Am Soc Echocardiogr 2015;28:853-909), which states that “An LVAD surveillance echo exam should be considered at approximately 2 weeks after device implantation or before index hospitalization discharge (whichever occurs first), followed by consideration of surveillance transthoracic echo (TTE) at 1, 3, 6, and 12 months post-implantation and every 6 to 12 months thereafter.”
- TTE imaging is not a definitive tool to identify an outflow graft twist obstruction. However, it can be used as an indirect assessment of obstruction by imaging the size of the left ventricle, the mitral valve and aortic valve opening, and diastolic velocity (inflow or outflow).
- A decrease in flow over time may be an indicator of Outflow Graft twist obstruction. If such a trend in flow is observed, or if flow velocity anywhere in the Outflow Graft exceeds 2 meters/sec (J Am Soc Echocardiogr 2015;28:853-909), more frequent surveillance echo exams than listed above, or other investigative methods, may be necessary.
- If a persistent low flow alarm (i.e., a low flow alarm not resolved after all relevant patient medical conditions having been ruled out as the cause) occurs at any time following implant, a Computed Tomography (CT) angiogram should be urgently obtained, if there are no contraindications, to identify a possible outflow graft twist occlusion.
- In the event that surgical repair of the Outflow Graft is needed due to a twist occlusion, the Outflow Graft Bend Relief should be reattached in its original state or repaired to prevent bending, abrasion or occlusion of the outflow graft at the graft’s attachment point to the pump.
Customers who want more information about this recall can contact their local Abbott Mechanical Circulatory Support (MCS) Clinical Specialist or MCS HeartLine at 1-800-456-1477, which is available 24 hours a day, 7 days a week.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:
- Complete and submit the report Online: www.fda.gov/MedWatch/report
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178